NCT01586117

A Phase II Study of Amifostine for the Prevention of Acute Radiation-Induced Rectal Toxicity

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Chinese Academy of Medical Sciences · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the effect of intrarectal Amifostine administration on acute radiation-induced rectal toxicity in pre-operative chemo-radiotherapy.

Detailed description

To evaluate the different use way of intrarectal Amifostine administration on acute radiation-induced rectal toxicity in pre-operative chemo-radiotherapy.

Conditions

• Rectal Cancer

Interventions

Type	Name	Description
DRUG	Amifostine	intrarectal Amifostine administration 1500mg QD x 5 weeks

Timeline

• Start date: 2012-02-01
• Primary completion: 2013-12-01
• Completion: 2014-12-01
• First posted: 2012-04-26
• Last updated: 2013-08-15

Locations

1 site across 1 country: China